Clinical trial
Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
NCT00030381 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00030381 |
|---|---|
| Title | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis |
| Official title | Phase I Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Primary Systemic Amyloidosis |
| Intervention type | Drug, Other |
| Interventions | 4'-iodo-4'-deoxydoxorubicin, pharmacological study |
| Enrollment | 22 |
| Start date | Dec 1, 2001 |
| Primary completion | Jan 1, 2003 |
| First posted | Sep 17, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: